Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA

Blood Cancer J. 2023 Jul 26;13(1):113. doi: 10.1038/s41408-023-00885-9.

Authors

Royston Ponraj¹, Adam Bryant^{2

3}, Lindsay Dunlop^{2

3

4}, Heather Range⁵, Cherry Cobrador⁵, Silvia Ling^{2

3

4}, Danny Hsu^{2

3}

Affiliations

¹ Haematology Department, Liverpool Hospital, Sydney, Australia. royston.ponraj@health.nsw.gov.au.
² Haematology Department, Liverpool Hospital, Sydney, Australia.
³ School of Medicine, University of New South Wales, Sydney, Australia.
⁴ School of Medicine, Western Sydney University, Sydney, Australia.
⁵ Department of Pharmacy, Liverpool Hospital, Sydney, Australia.

No abstract available

Publication types

Letter

MeSH terms

Hemolysis*
Humans
Oligopeptides / adverse effects
Thrombotic Microangiopathies* / chemically induced
Thrombotic Microangiopathies* / diagnosis

Substances

carfilzomib
Oligopeptides